WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 12/06/2025			5-day change	1st Jan Change
67.71 ^CNY	+4.09%		+3.98%	+23.02%

05/06	JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX	RE
26/05	WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year	MT

Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023

Published on 09/05/2024 at 17:01

WuXi AppTec Co., Ltd. proposed final cash dividend payment of RMB 9.8974 per 10 share for the financial year ended 31 December 2023 at its shareholders' meeting to be held on 12 June 2024. Ex-dividend date: 17 June 2024. Record date: 25 June 2024.

Latest news about WuXi AppTec Co., Ltd.

JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX	05/06	RE
WuXi AppTec Cuts Conversion Price of Zero-Coupon Bonds Due This Year	26/05	MT
JPMorgan Chase's Long Position In H Shares Of WuXi Apptec Decreases To 5.53% - HKEX	15/05	RE
WuXi AppTec Chairman Tops China's A-List for Highest Pay in 2024	09/05	MT
UBS Group's Long Position In H Shares Of WuXi Apptec Decreases To 5.79% - HKEX	02/05	RE
WuXi AppTec Co., Ltd., Q1 2025 Earnings Call, Apr 29, 2025	29/04
WuXi AppTec's Q1 Profit Balloons 89%	28/04	MT
Earnings Flash (2359) Wuxi AppTec Reports Q1 Revenue RMB9.65B	28/04	MT
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Year 2025	28/04	CI
WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	28/04	CI
Wuxi Apptec Q1 Net Profit Up 89.1% Y/Y	28/04	RE
UBS Group's Long Position In H-Shares Of Wuxi Apptec Decreased - HKEX	17/04	RE
UBS Group's Long Position In H Shares Of WuXi AppTec Increases To 7.30% - HKEX	16/04	RE
Morgan Stanley's Long Position In H Shares Of WuXi AppTec Reduces To 3.17% - HKEX	16/04	RE
UBS Group AG Increases Long Position In H Shares Of WuXi AppTec To 6.67% On April 9 From 5.89% - HKEX	15/04	RE
Morgan Stanley Increases Long Position In H Shares Of WuXi AppTec To 5.17% On April 9 From 4.30% - HKEX	15/04	RE
WuXi AppTec Receives Loan Commitment Letter For A-Share Buyback	09/04	RE
WuXi AppTec Proposes 1 Billion Yuan A Share Buyback	09/04	MT
WuXi AppTec Co., Ltd. announces an Equity Buyback for CNY 1,000 million worth of its shares.	08/04	CI
WuXi AppTec Co., Ltd. authorizes a Buyback Plan.	08/04	CI
WuXi AppTec Offloads 4.23% Stake in WuXi XDC Cayman	02/04	MT
WuXi AppTec Announces Disposal Of Certain Share Assets In WuXi XDC	02/04	RE
WuXi AppTec Sells 50.8 Million Shares In WuXi XDC Cayman	02/04	RE
Dongfeng Motor Group Company Limited Announces Resignation of Zhou Zhiping as Executive Director and President	26/03	CI
Jefferies Adjusts WuXi AppTec's Price Target to HK$87.40 From HK$71, Keeps at Buy	20/03	MT

Chart WuXi AppTec Co., Ltd.

Duration

Period

603259: Dynamic Chart

Company Profile

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Employees

39,414

Sector

Biotechnology & Medical Research

Calendar

04/08 - Q2 2025 Earnings Release (Projected)

More about the company